Investor group commits $30 mln to merged OvaScience and Millendo
An investor syndicate that includes New Enterprise Associates, Frazier Healthcare Partners, Roche Venture Fund, Innobio managed by Bpifrance, Osage University Partners, Altitude Life Science Ventures, Adams Street Partners, and Longwood Fund has committed to invest $30 million in the newly merged OvaScienceSM and Millendo Therapeutics. OvaScience is a developer of treatments for women and couples struggling with infertility while Millendo Therapeutics Inc is a clinical-stage biopharmaceutical company focused on treating orphan endocrine diseases. The newly combined company is expected to operate under the name Millendo Therapeutics and trade on the NASDAQ under the ticker symbol "MLND."
9 August 2018•1 min read
